Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Abstract
Major advances have been made in CRC treatment in recent years, especially in molecularly driven therapies and immunotherapy. Despite this, a large number of advanced colorectal cancer patients do not benefit from these treatments and their prognosis remains poor. The landscape of DNA damage response (DDR) alterations is emerging as a novel target for treatment in different cancer types. PARP inhibitors have been approved for the treatment of ovarian, breast, pancreatic, and prostate cancers carrying deleterious BRCA1/2 pathogenic variants or homologous recombination repair (HRR) deficiency (HRD). Recent research reported on the emerging role of HRD in CRC and showed that alterations in these genes, either germline or somatic, are carried by up to 15–20% of CRCs. However, the role of HRD is still widely unknown, and few data about their clinical impact are available, especially in CRC patients. In this review, we report preclinical and clinical data currently available on DDR inhibitors in CRC. We also emphasize the predictive role of DDR mutations in response to platinum-based chemotherapy and the potential clinical role of DDR inhibitors. More preclinical and clinical trials are required to better understand the impact of DDR alterations in CRC patients and the therapeutic opportunities with novel DDR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Various preclinical studies have demonstrated PARP inhibitors to also be effective in CRC cells; however, the sensitivity may depend on the status of certain genes involved in DDR [132].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“WEE1 is a tyrosine kinase that regulates the G2/M checkpoint of the cell cycle by preventing cells with DNA damage from entering mitosis, and so inhibiting WEE1 could sensitize tumors to DNA-damaging therapies [132].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 2×
“Efforts to develop molecular biomarkers of HRD have included transcriptomic signatures [66], mutational signatures [67], BRCA1 and RAD51 promoter hypermethylation [68], and functional biomarkers.”
BackgroundComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · cited 2×
“The last mediator involved is DNA-PK, which, after its recruitment and activation by the complex Ku70/Ku80 DSBs, provides access to end processing enzymes, such as ARTEMIS [110], and phosphorylates XRCC4/LIG4, which promotes the re-ligation of the broken ends with the help of the stimulatory factor XLF [111].”
BackgroundESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 1×
“Currently, the most common treatment used in metastatic colorectal cancer (mCRC) is represented by chemotherapy regimens constituting oxaliplatin, 5-fluorouracil, and/or irinotecan in combination with targeted agents including bevacizumab or aflibercept (antiangiogenic agents) and, according to the RAS/BRAF status, ce…”
BackgroundPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · cited 1×
“After the publication of the results of the phase 3 KEYNOTE-177 trial, for mismatch repair-deficient (MMR-deficient)/MSI-high mCRC, a first-line regiment with pembrolizumab has become the new standard of care [15].”
BackgroundOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
Rawla, P., Sunkara, T., & Barsouk, A. (2019) · Gastroenterology Review · doi:10.5114/pg.2018.81072 · Cited by 2,323
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302 · cited 1×
“Regarding gastrointestinal (GI) tract tumors, promising results have been reported with olaparib as maintenance therapy after platinum-based chemotherapy in patients with BRCA1/2-mutated pancreatic cancer (POLO trial) [22,54].”
BackgroundDNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Mechanisms of DNA damage, repair, and mutagenesis
Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
Playing the End Game: DNA Double-Strand Break Repair Pathway Choice
Chapman, J. R., Taylor, M. R. G., & Boulton, S. J. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.07.029 · Cited by 1,625
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · cited 1×
“After a first-line therapy with doublet-CT plus bevacizumab, BRAF-mutated, MSS mCRC should also receive a secondline treatment with encorafenib + cetuximab [10].”
DNA double-strand break repair-pathway choice in somatic mammalian cells
Scully, R., Panday, A., Elango, R., & Willis, N. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0152-0 · Cited by 1,457
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196 · cited 2×
“, BRCA1 or RAD51 methylation or mutation in other HRR genes: 48% and 11%, respectively) [71].”
BackgroundState-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T. A., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,136
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086 · cited 1×
“However, despite their high sensitivity in detecting BRCA-deficient tumors, ‘Signature 3′ and HRDetect failed to detect other functionally relevant mutations in other HR pathways [73].”
BackgroundSartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016 · cited 1×
“Moreover, mCRC HER2-mutated patients may benefit from treatment with lapatinib or trastuzumab in different settings; phase 3 trials are required to confirm the preliminary antitumoral efficacy [11,12].”
BackgroundIntegrative clinical genomics of metastatic cancer
Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature · doi:10.1038/nature23306 · Cited by 863 · cited 1×
“2%, 75% of which were DDR-related mutations [45].”
BackgroundMGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01015 · Cited by 728 · cited 1×
“Moreover, the combination of anti-PD1 (nivolumab) plus anti-CTLA4 (ipilimumab) has been tested in a first-line setting, with promising results in terms of PFS and OS in a phase 2 study [16,17].”
BackgroundPARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
Kaina, B., Christmann, M., Naumann, S., & Roos, W. P. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.03.008 · Cited by 663
Early‐onset colorectal cancer in young individuals
Mauri, G., Sartore‐Bianchi, A., Russo, A., Marsoni, S., Bardelli, A., & Siena, S. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12417 · Cited by 634
The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
Goldstein, M., & Kastan, M. B. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-081313-121208 · Cited by 590 · cited 3×
“Members of this family are ATM, ataxia telangiectasia and Rad3-related protein (ATR), and DNA-dependent kinase (DNAPK) [106].”
BackgroundInfluentialByers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y. H., Diao, L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0112 · Cited by 557
DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation
Difilippantonio, M. J., Zhu, J., Chen, H. T., Meffre, E., Nussenzweig, M. C., Max, E. E., Ried, T., & Nussenzweig, A. (2000) · Nature · doi:10.1038/35006670 · Cited by 547
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
Yurgelun, M. B., Kulke, M. H., Fuchs, C. S., Allen, B. A., Uno, H., Hornick, J. L., Ukaegbu, C. I., Brais, L. K., McNamara, P. G., Mayer, R. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0012 · Cited by 524
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0849 · Cited by 522 · cited 1×
“Many studies on PARP inhibitors have observed objective responses in patients with HRD tumors harboring non-BRCA-related mutations [24,64,74–76], such as ATM, CHEK, and ATR, as well as other genes involved in chromatin remodeling such as ARID1A [77] and BAP1 [78,79], or transcriptional regulators of DDR genes such as…”
BackgroundPrevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types
Heeke, A. L., Pishvaian, M. J., Lynce, F., Xiu, J., Brody, J. R., Chen, W.-J., Baker, T. M., Marshall, J. L., & Isaacs, C. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00286 · Cited by 467
Siena, S., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00086-3 · Cited by 422
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Perez-Lopez, R., Dolling, D., Robinson, D. R., Sandhu, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0261 · Cited by 421
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Yu, H., Pak, H., Hammond-Martel, I., Ghram, M., Rodrigue, A., Daou, S., Barbour, H., Corbeil, L., Hébert, J., Drobetsky, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309085110 · Cited by 383
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373 · cited 2×
“Many studies on PARP inhibitors have observed objective responses in patients with HRD tumors harboring non-BRCA-related mutations [24,64,74–76], such as ATM, CHEK, and ATR, as well as other genes involved in chromatin remodeling such as ARID1A [77] and BAP1 [78,79], or transcriptional regulators of DDR genes such as…”
BackgroundBiomarkers for Homologous Recombination Deficiency in Cancer
Hoppe, M. M., Sundar, R., Tan, D. S. P., & Jeyasekharan, A. D. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy085 · Cited by 329
Watkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327
Jiang, M., Jia, K., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., He, Y., & Zhou, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.003 · Cited by 320
53BP1, BRCA1, and the Choice between Recombination and End Joining at DNA Double-Strand Breaks
Daley, J. M., & Sung, P. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01639-13 · Cited by 318 · cited 1×
“The 53BP1 protein triggers the NHEJ mechanism in repairing programmed DSBs, whereas BRCA1 antagonizes 53BP1 and activates DSB resection and the HRR mechanism [40].”
BackgroundConcise update on colorectal cancer epidemiology
Mattiuzzi, C., Sanchis-Gomar, F., & Lippi, G. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.91 · Cited by 311
Bang, Y.-J., Im, S.-A., Lee, K.-W., Cho, J. Y., Song, E.-K., Lee, K. H., Kim, Y. H., Park, J. O., Chun, H. G., Zang, D. Y., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0320 · Cited by 290
Mismatch Repair Pathway, Genome Stability and Cancer
Pećina-Šlaus, N., Kafka, A., Salamon, I., & Bukovac, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00122 · Cited by 278
Leijen, S., van Geel, R. M. J. M., Pavlick, A. C., Tibes, R., Rosen, L., Razak, A. R. A., Lam, R., Demuth, T., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5991 · Cited by 264
Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259 · cited 1×
“, 2011 1 CRC, 5 patients Veliparib + topotecan ORR 0% [98]”
Genome-wide transcriptome profiling of homologous recombination DNA repair
Peng, G., Chun-Jen Lin, C., Mo, W., Dai, H., Park, Y.-Y., Kim, S. M., Peng, Y., Mo, Q., Siwko, S., Hu, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4361 · Cited by 229
Stewart, C. A., Tong, P., Cardnell, R. J., Sen, T., Li, L., Gay, C. M., Masrorpour, F., Fan, Y., Bara, R. O., Feng, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15338 · Cited by 227
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
Lu, Y., Kwintkiewicz, J., Liu, Y., Tech, K., Frady, L. N., Su, Y.-T., Bautista, W., Moon, S. I., MacDonald, J., Ewend, M. G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2773 · Cited by 201
Harnessing DNA Double-Strand Break Repair for Cancer Treatment
Trenner, A., & Sartori, A. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01388 · Cited by 193
The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer
Sishc, B., & Davis, A. (2017) · Cancers · doi:10.3390/cancers9070081 · Cited by 181
Samol, J., Ranson, M., Scott, E., Macpherson, E., Carmichael, J., Thomas, A., & Cassidy, J. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9682-9 · Cited by 158
Cancer genetics, precision prevention and a call to action
Turnbull, C., Sud, A., & Houlston, R. S. (2018) · Nature Genetics · doi:10.1038/s41588-018-0202-0 · Cited by 155
Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study
the Hereditary Breast Cancer Study Group, Phelan, C. M., Iqbal, J., Lynch, H. T., Lubiński, J., Gronwald, J., Møller, P., Ghadirian, P., Foulkes, W. D., Armel, S. R., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.741 · Cited by 152
BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis
Oh, M., McBride, A., Yun, S., Bhattacharjee, S., Slack, M., Martin, J. R., Jeter, J., & Abraham, I. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy148 · Cited by 141
Inherited DNA-Repair Defects in Colorectal Cancer
AlDubayan, S. H., Giannakis, M., Moore, N. D., Han, G. C., Reardon, B. M., Hamada, T., Mu, X. J., Nishihara, R., Qian, Z., Liu, L., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.01.018 · Cited by 134
Kim, R., Kwon, M., An, M., Kim, S. T., Smith, S. A., Loembé, A., Mortimer, P. G. S., Armenia, J., Lukashchuk, N., Shah, N., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.10.009 · Cited by 134
Yap, T. A., Krebs, M., Postel-Vinay, S. C., El-Khoueiry, A. B., Soria, J., Lopez, J. S., Berges, A., Cheung, S. Y. A., Irurzun‐Arana, I., Goldwin, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1032 · Cited by 133
Exploiting DNA repair defects in colorectal cancer
Reilly, N. M., Novara, L., Di Nicolantonio, F., & Bardelli, A. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12467 · Cited by 130
Macedo, L. T., da Costa Lima, A. B., & Sasse, A. D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-89 · Cited by 126
Kubota, E., Williamson, C. T., Ye, R., Elegbede, A., Peterson, L., Lees-Miller, S. P., & Bebb, D. G. (2014) · Cell Cycle · doi:10.4161/cc.29212 · Cited by 124
ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
Wang, C., Jette, N., Moussienko, D., Bebb, D. G., & Lees-Miller, S. P. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.01.007 · Cited by 122
Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets
Gilbert, D. C., Chalmers, A. J., & El-Khamisy, S. F. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.498 · Cited by 118
Seligmann, J. F., Fisher, D. J., Brown, L. C., Adams, R. A., Graham, J., Quirke, P., Richman, S. D., Butler, R., Domingo, E., Blake, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01435 · Cited by 117
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2409 · Cited by 115 · cited 2×
“However, this approach requires an engineered system based on plasmid transfection, making it not easily feasible on a routine basis [83].”
BackgroundDevelopment and Characterization of a Wee1 Kinase Degrader
Li, Z., Pinch, B. J., Olson, C. M., Donovan, K. A., Nowak, R. P., Mills, C. E., Scott, D. A., Doctor, Z. M., Eleuteri, N. A., Chung, M., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.10.013 · Cited by 103
Mao, C., Liao, R.-Y., Qiu, L., Wang, X.-W., Ding, H., & Chen, Q. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0351-4 · Cited by 100
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
Gilardini Montani, M. S., Prodosmo, A., Stagni, V., Merli, D., Monteonofrio, L., Gatti, V., Gentileschi, M. P., Barilà, D., & Soddu, S. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-95 · Cited by 94
Kim, S. T., Smith, S. A., Mortimer, P. G. S., Loembé, A., Cho, H., Kim, K., Smith, C. L., Willis, S. E., Irurzun‐Arana, I., Berges, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0251 · Cited by 88
Alterations of DNA damage repair in cancer: from mechanisms to applications
Jiang, M., Jia, K., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., He, Y., & Zhou, C. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2920 · Cited by 87
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
Mauri, G., Arena, S., Siena, S., Bardelli, A., & Sartore-Bianchi, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.027 · Cited by 86
Leichman, L., Groshen, S., O’Neil, B. H., Messersmith, W., Berlin, J., Chan, E., Leichman, C. G., Cohen, S. J., Cohen, D., Lenz, H.-J., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0319 · Cited by 82
Update on Hereditary Colorectal Cancer: Improving the Clinical Utility of Multigene Panel Testing
Lorans, M., Dow, E., Macrae, F., Winship, I., & Buchanan, D. D. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.01.001 · Cited by 80
Ha, D.-H., Min, A., Kim, S., Jang, H., Kim, S. H., Kim, H.-J., Ryu, H. S., Ku, J.-L., Lee, K.-H., & Im, S.-A. (2020) · Scientific Reports · doi:10.1038/s41598-020-66018-5 · Cited by 78 · cited 1×
“Therefore, the inhibition of Wee1 can sensitize tumors to DNA-damaging therapies [112,113].”
BackgroundGolan, T., Hammel, P. R., Reni, M., Cutsem, E. V., Macarulla, T. M., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.378 · Cited by 78
Moretto, R., Elliott, A., Zhang, J., Arai, H., Germani, M. M., Conca, V., Xiu, J., Stafford, P., Oberley, M., Abraham, J., et al. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab169 · Cited by 77
Czito, B. G., Deming, D. A., Jameson, G., Mulcahy, M. F., Vaghefi, H., Dudley, M. W., Holen, K. D., DeLuca, A., Mittapalli, R. K., Munasinghe, W. P., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30012-2 · Cited by 76
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines
Davidson, D. L., Wang, Y., Aloyz, R. S., & Panasci, L. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9886-7 · Cited by 73
Pishvaian, M. J., Slack, R. S., Jiang, W., He, A. R., Hwang, J. J., Hankin, A., Dorsch‐Vogel, K., Kukadiya, D., Weiner, L. M., Marshall, J. L., et al. (2018) · Cancer · doi:10.1002/cncr.31309 · Cited by 69
Parrotta, R., Okonska, A., Ronner, M., Weder, W., Stahel, R., Penengo, L., & Felley-Bosco, E. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.023 · Cited by 65
Cullinane, C. M., Creavin, B., O’Connell, E., Kelly, L., O’Sullivan, M. J., Corrigan, M. A., & Redmond, H. P. (2020) · British journal of surgery · doi:10.1002/bjs.11603 · Cited by 65
Tahara, M., Inoue, T., Sato, F., Miyakura, Y., Horie, H., Yasuda, Y., Fujii, H., Kotake, K., & Sugano, K. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0683 · Cited by 64
Russo, A. D., Incorvaia, L., Capoluongo, E., Tagliaferri, P., Galvano, A., Re, M. D., Malapelle, U., Chiari, R., Conte, P., Danesi, R., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103567 · Cited by 64
Sayed, I. M., Chakraborty, A., El‐Hafeez, A. A. A., Sharma, A., Sahan, A. Z., Huang, W. J. M., Sahoo, D., Ghosh, P., Hazra, T. K., & Das, S. (2020) · Cells · doi:10.3390/cells9091980 · Cited by 60
Gorbunova, V., Beck, J. T., Hofheinz, R.-D., Garcia-Alfonso, P., Nechaeva, M., Cubillo Gracian, A., Mangel, L., Elez Fernandez, E., Deming, D. A., Ramanathan, R. K., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0343-z · Cited by 57
Smeby, J., Kryeziu, K., Berg, K. C. G., Eilertsen, I. A., Eide, P. W., Johannessen, B., Guren, M. G., Nesbakken, A., Bruun, J., Lothe, R. A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102923 · Cited by 50
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Arai, H., Elliott, A., Xiu, J., Wang, J., Battaglin, F., Kawanishi, N. K., Soni, S., Zhang, W., Millstein, J., Sohal, D. P. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3635 · Cited by 49
Genther Williams, S. M., Kuznicki, A. M., Andrade, P., Dolinski, B. M., Elbi, C., O’Hagan, R. C., & Toniatti, C. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0162-8 · Cited by 47
Structural Basis of DNA Ligase IV-Artemis Interaction in Nonhomologous End-Joining
De Ioannes, P., Malu, S., Cortes, P., & Aggarwal, A. K. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.11.004 · Cited by 47
Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib
Augustine, T. A., Maitra, R., Zhang, J., Nayak, J., & Goel, S. (2019) · Investigational New Drugs · doi:10.1007/s10637-018-00717-9 · Cited by 45
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer
Collins, T. S., & Hurwitz, H. I. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.09.026 · Cited by 42
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
Toss, A., Tenedini, E., Piombino, C., Venturelli, M., Marchi, I., Gasparini, E., Barbieri, E., Razzaboni, E., Domati, F., Caggia, F., et al. (2021) · Genes · doi:10.3390/genes12050616 · Cited by 41
Sundar, R., Miranda, S., Rodrigues, D. N., Chénard-Poirier, M., Dolling, D. I., Clarke, M., Figueiredo, I., Bertan, C. M., Yuan, W., Ferreira, A., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.011 · Cited by 41
Xu, K., Chen, Z., Cui, Y. W., Qin, C., He, Y., & Song, X. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s89154 · Cited by 38
McAndrew, E. N., Lepage, C. C., & McManus, K. J. (2016) · Oncotarget · doi:10.18632/oncotarget.13654 · Cited by 36
Özden, Ö., Bishehsari, F., Bauer, J. I., Park, S., Jana, A., Baik, R., Sporn, J. C., Staudacher, J. J., Yazıcı, C., Krett, N. L., et al. (2016) · Scientific Reports · doi:10.1038/srep26273 · Cited by 34
First-line therapy for mCRC — the influence of primary tumour location on the therapeutic algorithm
Cremolini, C., Antoniotti, C., Moretto, R., Masi, G., & Falcone, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.219 · Cited by 33
Berlin, J., Ramanathan, R. K., Strickler, J. H., Subramaniam, D. S., Marshall, J. L., Kang, Y., Hetman, R., Dudley, M. W., Zeng, J., Nickner, C., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0003-3 · Cited by 32
A profile on the FoundationFocus CDxBRCA tests
Ford, L., Wolford, J. E., Brown, S. M., & Randall, L. M. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1701438 · Cited by 30
Strickler, J. H., Ng, K., Cercek, A., Fountzilas, C. K., Sanchez, F. A., Hubbard, J. M., Wu, C. S.-Y., Siena, S., Tabernero, J. M., Cutsem, E. V., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.tps153 · Cited by 29
Greene, J., Nguyen, A., Bagby, S. M., Jones, G. N., Tai, W., Quackenbush, K. S., Schreiber, A., Messersmith, W. A., Devaraj, K. M., Blatchford, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22920 · Cited by 26 · cited 1×
“[95] tested whether an ATM inhibitor (AZ31) would enhance sensitivity to irinotecan in CRC cell lines and CRC patient-derived xenografts.”
BackgroundTargeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives
Zimmer, K., Kocher, F., Puccini, A., & Seeber, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.662055 · Cited by 25
Self-citationFuningana, I.-G., Reinius, M. A. V., Petrillo, A., Ang, J. E., & Brenton, J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.008 · Cited by 23
First international workshop of the ATM and cancer risk group (4-5 December 2019)
Lesueur, F., Easton, D. F., Renault, A., Tavtigian, S. V., Bernstein, J. L., Kote‐Jarai, Z., Eeles, R. A., Plaseska-Karanfia, D., Feliubadaló, L., Spanish ATM working group, et al. (2021) · Familial Cancer · doi:10.1007/s10689-021-00248-y · Cited by 23
Yoshino, T., Bartolomeo, M. D., Raghav, K. P. S., Masuishi, T., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z. A., Élez, E., Rodríguez, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.119 · Cited by 21
Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations
Hannan, Z. M., Yu, S., Domchek, S. M., Mamtani, R., & Reiss, K. A. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa121 · Cited by 20
ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer
Bakkenist, C. J., Lee, J. J., & Schmitz, J. C. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.09.001 · Cited by 19
Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers
Grinshpun, A., Halpern, N., Granit, R. Z., Hubert, A., Hamburger, T., Laitman, Y., Shacham‐Shmueli, E., Peerless, Y., Friedman, E., & Peretz, T. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-017-0067-1 · Cited by 15
Siena, S., Demetri, G. D., Doebele, R. C., Chae, Y., Conkling, P., Garrido‐Laguna, I., Garrido, P., Rolfo, C. D., Sigal, D. S., Eng, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz154.023 · Cited by 13
Aguirre, E., Amillano, K., Cortés, A., Juan, M. J., Márquez, A., Ruiz, M., Servitja, S., Urrutikoetxea, A., Llombart‐Cussac, A., Pérez-García, J. M., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct165 · Cited by 11
Antoniotti, C., Moretto, R., Rossini, D., Masi, G., Falcone, A., & Cremolini, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102135 · Cited by 6
Kumar, M., Shukla, V. K., Misra, P. K., & Raman, M. J. (2018) · PubMed Central · doi:10.22088/ijmcm.bums.7.2.119 · Cited by 4
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Various preclinical studies have demonstrated PARP inhibitors to also be effective in CRC cells; however, the sensitivity may depend on the status of certain genes involved in DDR [132].”
InfluentialPuccini, A., Poorman, K. A., Catalano, F., Seeber, A., Goldberg, R. M., Salem, M. E., Shields, A. F., Berger, M. D., Battaglin, F., Tokunaga, R., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02350-6 · Cited by 60
Self-citationUpdate on Emerging Therapies for Advanced Colorectal Cancer
Alese, O. B., Wu, C. S.-Y., Chapin, W. J., Ulanja, M. B., Zheng-Lin, B., Amankwah, M., & Eads, J. R. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389574 · Cited by 55
Kumar, K., Kumar, S., Datta, K., Fornace, A. J., & Suman, S. (2023) · Current Oncology · doi:10.3390/curroncol30060416 · Cited by 45
Ma, W., & Zhou, S. (2025) · Biomolecules · doi:10.3390/biom15020168 · Cited by 37
Metadata
- Authors
- Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A.
- Affiliations
- Ospedale Policlinico San Martino (IT)
- Corresponding author
- Puccini, Alberto
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-03-09
- Volume
- 14
- Issue
- 6
- Pages
- 1388
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8946235
- OpenAlex
- W4220744860
- Cited by
- 44
- References
- 117
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 7
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- DNA damage response, colorectal cancer, DDR inhibitors, homologous recombination deficiency, PARP inhibitors, platinum-based chemotherapy, predictive biomarkers, targeted therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.